978 related articles for article (PubMed ID: 21527125)
1. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S
Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
5. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
8. Effects of outpatient treatment on risk of arrest of adults with serious mental illness and associated costs.
Van Dorn RA; Desmarais SL; Petrila J; Haynes D; Singh JP
Psychiatr Serv; 2013 Sep; 64(9):856-62. PubMed ID: 23677480
[TBL] [Abstract][Full Text] [Related]
9. The case for atypical antipsychotics in bipolar disorder.
Shattell M; Keltner NL
Perspect Psychiatr Care; 2004; 40(1):34-8. PubMed ID: 15147051
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
11. A model of anticholinergic activity of atypical antipsychotic medications.
Chew ML; Mulsant BH; Pollock BG; Lehman ME; Greenspan A; Kirshner MA; Bies RR; Kapur S; Gharabawi G
Schizophr Res; 2006 Dec; 88(1-3):63-72. PubMed ID: 16928430
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Melnik T; Soares BG; Puga ME; Atallah AN
Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366
[TBL] [Abstract][Full Text] [Related]
13. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
14. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Pathak P; West D; Martin BC; Helm ME; Henderson C
Psychiatr Serv; 2010 Feb; 61(2):123-9. PubMed ID: 20123816
[TBL] [Abstract][Full Text] [Related]
16. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
Chen L; McCombs JS; Park J
Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
[TBL] [Abstract][Full Text] [Related]
17. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Hooshmand F; Miller S; Dore J; Wang PW; Hill SJ; Portillo N; Ketter TA
J Affect Disord; 2014 Feb; 155():283-7. PubMed ID: 24314912
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.
Berger A; Edelsberg J; Sanders KN; Alvir JM; Mychaskiw MA; Oster G
BMC Psychiatry; 2012 Aug; 12():99. PubMed ID: 22856540
[TBL] [Abstract][Full Text] [Related]
19. Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Boaz TL; Constantine RJ; Robst J; Becker MA; Howe AM
J Clin Psychiatry; 2011 Aug; 72(8):1079-85. PubMed ID: 21034690
[TBL] [Abstract][Full Text] [Related]
20. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
